Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.

Journal: F&S reports
Published Date: Nov 10, 2020

Abstract

OBJECTIVE: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.

Authors

  • Jared C Robins
    Northwestern University, Chicago, Illinois.
  • Andrew F Khair
    Ferring Pharmaceuticals Inc., Parsippany, New Jersey.
  • Eric A Widra
    Shady Grove Fertility, Rockville, Maryland.
  • Michael M Alper
    Boston IVF, Waltham, Massachusetts.
  • Winnie W Nelson
    Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Eric D Foster
    Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Anshul Sinha
    Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Masakazu Ando
    Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Patrick W Heiser
    Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
  • Gaurang S Daftary
    Ferring Pharmaceuticals Inc., Parsippany, New Jersey.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals